Metastatic breast cancer: Mechanisms and opportunities for cytology

Cytopathology

Volumn 25, Issue 4, 2014, Pages 225-230

  Martins, D ^a   Beca, F ^a,b   Schmitt, F ^a,c,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Breast cancer; Cytology; Fine needle aspiration; Immunocytochemistry; Metastasis; Molecular analysis

Indexed keywords

ANTIBODY SPECIFICITY; ASPIRATION CYTOLOGY; BREAST METASTASIS; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; BREAST NEOPLASMS; CYTODIAGNOSIS; FEMALE; METASTASIS; NEOPLASMS, SECOND PRIMARY; PATHOLOGY;

BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CYTODIAGNOSIS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, SECOND PRIMARY;

EID: 84904335201     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12158     Document Type: Review

References (36)

1. Shevde LA, Welch DR. Metastasis suppressor pathways - an evolving paradigm. Cancer Lett 2003;198:1-20.
2. van der Heiden-van der Loo M, Schaapveld M, Ho VK, et al. Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. Ann Oncol 2013;24:2794-801.
3. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Yang J, Mani SA, Donaher JL et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004;117:927-39.
6. De Leeuw WJ, Berx G, Vos CB et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997;183:404-11.
7. Paredes J, Albergaria A, Oliveira JT et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005;11:5869-77.
8. Ribeiro AS, Albergaria A, Sousa B et al. Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene 2010;29:392-402.
9. Ribeiro AS, Sousa B, Carreto L et al. P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol 2013;229:705-18.
10. Xue C, Wyckoff J, Liang F et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006;66:192-7.
11. Katz M, Amit I, Citri A et al. A reciprocal tensin3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 2007;9:961-9.
12. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009;9:302-12.
13. Beca F, Schmitt F. Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites. Cancer Cytopathol 2014; doi: 10.1002/cncy.21395. [Epub ahead of print].
14. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.
15. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
16. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
17. Lu X, Kang Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc Natl Acad Sci USA 2009;106:9385-90.
18. Kim MY, Oskarsson T, Acharyya S et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139:1315-26.
19. Amir E, Miller N, Geddie W et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-92.
20. Wilking U, Karlsson E, Skoog L et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011;125:553-61.
21. Cardoso F, Harbeck N, Fallowfield L et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-9.
22. Cyrta J, Andreiuolo F, Azoulay S et al. Pure and mixed mucinous carcinoma of the breast: fine needle aspiration cytology findings and review of the literature. Cytopathology 2013;24:377-84.
23. Jacquet SF, Balleyguier C, Garbay JR et al. Fine-needle aspiration cytopathology - an accurate diagnostic modality in mammary carcinoma with osteoclast-like giant cells: a study of 8 consecutive cases. Cancer Cytopathol 2010;118:468-73.
24. Schmitt F, Barroca H. Role of ancillary studies in fine-needle aspiration from selected tumors. Cancer Cytopathol 2012;120:145-60.
25. Annaratone L, Marchio C, Renzulli T et al. High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer. Transl Oncol 2012;5:180-9.
26. Andre F, Michiels S, Dessen P et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 2009;10:381-90.
27. Cano G, Milanezi F, Leitao D et al. Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 2003;29:207-11.
28. Marinsek ZP, Nolde N, Kardum-Skelin I et al. Multinational study of oestrogen and progesterone receptor immunocytochemistry on breast carcinoma fine needle aspirates. Cytopathology 2013;24:7-20.
29. Domanski AM, Monsef N, Domanski HA, Grabau D, Ferno M. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients. Cytopathology 2013;24:21-5.
30. Srebotnik KI, Us KM, Pogačnik A, Strojan Flezar M Optimization and validation of immunocytochemical detection of oestrogen receptors on cytospins prepared from FNA samples of breast cancer. Cytopathology 2014; doi: 10.1111/cyt.12143 [Epub ahead of print].
31. Niikura N, Odisio BC, Tokuda Y et al. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol 2013;10:711-9.
32. Gu M, Ghafari S, Zhao M. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens. Acta Cytol 2005;49:471-6.
33. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013;368:842-51.
34. Ulivi P, Romagnoli M, Chiadini E et al. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. Int J Oncol 2012;41:147-52.
35. Costa J, Gerhard R, Rossi E et al. Massive parallel sequencing to assess the mutational landscape of fine needle aspirate samples: a pilot study. Lab Invest 2013; 93:87A.
36. Young G, Wang K, He J et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013;121:688-94.